Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes.

Akome is working on AKO001, their psychedelic compound comprised of N,N-dimethyltryptamine (DMT) and a plant bioactive, which they believe will work in a complimentary way. Akome hopes that AKO001 will help mitigate neurological damage from ischemic strokes.

Akome is working on AKO001, their psychedelic compound comprised of N,N-dimethyltryptamine (DMT) and a plant bioactive, which they believe will work in a complimentary way

Ischemia is any reduction in blood flow resulting in decreased oxygen and nutrient supplies to a tissue, and ischemic strokes occur when a vessel supplying blood to the brain is obstructed. Ischemic strokes account for 87% of all strokes.

A provisional matter of composition patent application for AKO001 has been filed with the US Patent and Trademark Office under application 63147343.

“Our goal with the development of AKO001 is to reduce the damage from the number of life long disabling symptoms that can occur after experiencing a stroke. We look forward to continued development on this front and providing updates to the medical community on our progress,” stated Joel Shacker CEO of Core One Labs.

In 2014-2015, stroke related medical costs totalled $46 billion USD, and by 2030, many estimate that the costs will rise to a staggering $240 billion USD. According to the CDC, strokes are the fifth-leading cause of death in the US annually in a typical year, causing the death of 150,000 each year.

Akome hopes that these complimentary functions can aid in vivo replacement of neurons after neural injury, with the bioactive removing the damaged cells and the DMT binding the new, healthy cells with the rest of the brain’s functioning cells.

Akome hopes that the combination of DMT and their plant bioactive will be effective against ischemic strokes, as they note that the “bioactive shows evidence of promoting positive apoptotic processes”. “Apoptosis describes the orchestrated collapse of a cell characterised by membrane blebbing, cell shrinkage, condensation of chromatin, and fragmentation of DNA followed by rapid engulfment of the corpse by neighbouring cells.” Put simply, it is an organized cell death process, which allows the dead cells to be removed.

On the other hand, Akome claims their DMT “induces the formation of glial cells”, which “play an important role in maintaining synaptic homeostasis” and which has been described as the cellular “glue” of the brain’s nervous system.

Akome hopes that these complementary functions can aid in vivo replacement of neurons after neural injury, with the bioactive removing the damaged cells and the DMT binding the new, healthy cells with the rest of the brain’s functioning cells.

Following today’s news, Core One shares are up 5 cents and are currently trading at $0.74.

Full disclosure: Core One Labs is not an Equity Guru marketing client currently, although they used to be.

Written By:

Piers Eaton

Canadian, English, and American writer, interested in human behavior. Can usually be found on reading or on a walk. Passable musician and decent snowboarder.

More By This Author
Tags:
Biotech
Eaton
Health Science
Psychedelics
AKO001
Akome
Akome Biotech
Bioactive
Core One Labs
DMT
stroke
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x